NewAmsterdam Pharma Valuation
| NAMSW Stock | 10.49 0.94 9.84% |
At this time, the firm appears to be overvalued. NewAmsterdam Pharma secures a last-minute Real Value of USD8.13 per share. The latest price of the firm is USD10.49. Our model forecasts the value of NewAmsterdam Pharma from analyzing the firm fundamentals such as Operating Margin of (23.14) %, revenue of 45.56 M, and Return On Equity of -0.32 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that NewAmsterdam Pharma's price fluctuation is moderately volatile at this time. Calculation of the real value of NewAmsterdam Pharma is based on 3 months time horizon. Increasing NewAmsterdam Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NewAmsterdam stock is determined by what a typical buyer is willing to pay for full or partial control of NewAmsterdam Pharma. Since NewAmsterdam Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NewAmsterdam Stock. However, NewAmsterdam Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.49 | Real 8.13 | Hype 10.49 | Naive 11.98 |
The intrinsic value of NewAmsterdam Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NewAmsterdam Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NewAmsterdam Pharma helps investors to forecast how NewAmsterdam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NewAmsterdam Pharma more accurately as focusing exclusively on NewAmsterdam Pharma's fundamentals will not take into account other important factors: NewAmsterdam Pharma Total Value Analysis
NewAmsterdam Pharma is now projected to have takeover price of 0 with market capitalization of 0, debt of 448 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the NewAmsterdam Pharma fundamentals before making investing decisions based on enterprise value of the companyNewAmsterdam Pharma Investor Information
The company had not issued any dividends in recent years. NewAmsterdam Pharma had 1:1 split on the 23rd of November 2022. Based on the key measurements obtained from NewAmsterdam Pharma's financial statements, NewAmsterdam Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.NewAmsterdam Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NewAmsterdam Pharma has an asset utilization ratio of 5.27 percent. This indicates that the Company is making USD0.0527 for each dollar of assets. An increasing asset utilization means that NewAmsterdam Pharma is more efficient with each dollar of assets it utilizes for everyday operations.NewAmsterdam Pharma Profitability Analysis
The company reported the revenue of 45.56 M. Net Loss for the year was (241.6 M) with profit before overhead, payroll, taxes, and interest of 47.14 M.About NewAmsterdam Pharma Valuation
Our relative valuation model uses a comparative analysis of NewAmsterdam Pharma. We calculate exposure to NewAmsterdam Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NewAmsterdam Pharma's related companies.NewAmsterdam Pharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as NewAmsterdam Pharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 94.4 M |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.